Adma Biologics reported $732.48M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Adma Biologics USD 732.48M 48.28M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Novavax USD 888M 67.57M Sep/2026
Omeros USD 200.57M 34.59M Jun/2025
Takeda JPY 15.27T 391.77B Sep/2026